Lopa Patel, MD
Critical Care Medicine · Montclair, NJNPI 1447268677
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.3%), education and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Intuitive Surgical at 42.3% of the total. Reporting peaked in 2024 at $5,152 and has fallen 74.2% since, to $1,332 in 2025. Among critical care medicine clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 372 payments — averaging $26.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- GSK$2K
- AstraZeneca$1K
- Boehringer Ingelheim$441
- Insmed, Inc.$349
- Harmony Biosciences LLC$265
- plus $2K from 27 others
What the payments were for
- Travel & lodging$1,39114%
- Food & beverage$5,75358%
- Education$2,71327%
- Gifts$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 12 | $4,172 |
| GSK | 122 | $1,608 |
| AstraZeneca | 76 | $1,256 |
| Boehringer Ingelheim | 31 | $441 |
| Insmed, Inc. | 23 | $349 |
| Harmony Biosciences LLC | 12 | $265 |
| Medtronic | 2 | $197 |
| Mylan Specialty L.p. | 11 | $189 |
| Amgen(2 entities) | 11 | $171 |
| Axsome Therapeutics, Inc. | 9 | $151 |
| Philips North America LLC | 10 | $146 |
| Jazz Pharmaceuticals Inc. | 9 | $130 |
| Pulmonx Corporation | 3 | $115 |
| Viatris Specialty LLC | 4 | $75 |
| Sanofi-aventis U.S. LLC | 1 | $75 |
| Sunovion Pharmaceuticals Inc. | 6 | $70 |
| Mallinckrodt Hospital Products Inc. | 5 | $65 |
| Novartis | 3 | $46 |
| Shire North American Group Inc | 3 | $44 |
| Baxter Healthcare | 2 | $38 |
| Vifor Pharma, Inc. | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $31 |
| Grifols USA, LLC | 2 | $29 |
| Lilly USA, LLC | 1 | $22 |
| United Therapeutics Corporation | 1 | $21 |
| Verona Pharma, Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Covidien LP | 1 | $14 |
| Optinose US, Inc. | 1 | $13 |
| Sanofi | 1 | $12 |
| Circassia Inc. | 1 | $12 |
| Mallinckrodt Enterprises LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,102
How this compares
$9,865 in reported general payments places this provider in the 90th percentile of 254 critical care medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 459 | $367,715 |
| Breo ElliptaFluticasone/Vilanterol | 237 | $132,132 |
| ZemairaAlpha-1-Proteinase Inhibitor | 13 | $115,291 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 109 | $71,845 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 118 | $67,471 |
| Spiriva RespimatTiotropium Bromide | 68 | $46,831 |
| TezspireTezepelumab-Ekko | 11 | $45,200 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 52 | $38,340 |
| SymbicortBudesonide/Formoterol Fumarate | 44 | $19,421 |
| Spiriva HandihalerTiotropium Bromide | 18 | $16,092 |
| Advair HfaFluticasone Propion/Salmeterol | 24 | $14,568 |
| Incruse ElliptaUmeclidinium Bromide | 26 | $14,512 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 112 | $12,952 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 75 | $12,711 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 22 | $9,117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,608 | $586,899860 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $1,256 | $136,466164 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $441 | $85,171120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 254 critical care medicine providers in New Jersey.
Other critical care medicine in Montclair
- Fariborz RezaiLivingston$2.3M
- Eric TellerHackensack$217K
- R Phillip DellingerCamden$74K
- Raghad SaidHackensack$48K
- Neha VagadiaMarlton$31K
- Mark RamzyWest Orange$31K
- Shawana HussainCamden$19K
- Theodore PlushCamden$18K
- Martin LansangFlemington$18K
- Stephen TrzeciakCamden$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.